Jaguar Health, Inc. (JAGX)
$0.21-$0.01 (-5.25%) Latest session
Latest JAGX Insider Trades
Lisa A. Conte - OfficerOpen-market purchase$450.00M
Lisa A. Conte - OfficerLisa A. Conte - OfficerJaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
No Form 4 activity for JAGX in the last 90 days.
20 Form 4 filings on record, the earliest from Oct 10, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| John Micek | Grant or award | Common Stock | 7,377 | $0.00 | - | |
| John Micek | Grant or award | Stock Option (right to buy) | 7,377 | $0.00 | - | |
| Steven R. King - Officer | Grant or award | Common Stock | 11,740 | $0.00 | - | |
| Steven R. King - Officer | Grant or award | Stock Option (right to buy) | 11,740 | $0.00 | - | |
| Lisa A. Conte - Officer | Grant or award | Common Stock | 28,592 | $0.00 | - | |
| Lisa A. Conte - Officer | Grant or award | Stock Option (right to buy) | 28,592 | $0.00 | - | |
| Jonathan S. Wolin - Officer | Grant or award | Common Stock | 11,740 | $0.00 | - | |
| Jonathan S. Wolin - Officer | Grant or award | Stock Option (right to buy) | 11,740 | $0.00 | - | |
| James J. Bochnowski | Derivative | Convertible Promissory Note | 27,002 | $71,590,909.09 | $4.05B | |
| James J. Bochnowski | Grant or award | Convertible Promissory Note | 28,388 | $71,590,909.09 | $4.26B | |
| James J. Bochnowski | Grant or award | Warrant to Purchase Common Stock | 54,786 | - | - | |
| John Micek | Derivative | Convertible Promissory Note | 9,000 | $23,863,636.36 | $450.00M | |
| John Micek | Grant or award | Convertible Promissory Note | 9,462 | $23,863,636.36 | $473.10M | |
| John Micek | Grant or award | Warrant to Purchase Common Stock | 18,262 | - | - | |
| Lisa A. Conte - Officer | Derivative | Convertible Promissory Note | 9,000 | $23,863,636.36 | $450.00M | |
| Lisa A. Conte - Officer | Grant or award | Convertible Promissory Note | 9,462 | $23,863,636.36 | $473.10M | |
| Lisa A. Conte - Officer | Grant or award | Warrant to Purchase Common Stock | 18,262 | - | - | |
| Lisa A. Conte - Officer | Option exercise | Common Stock | 2 | - | - | |
| Lisa A. Conte - Officer | Option exercise | Restricted stock units | 2 | $0.00 | - | |
| Lisa A. Conte - Officer | Open-market purchase | Convertible Promissory Note | 9,000 | $23,863,636.36 | $450.00M | |
| Lisa A. Conte - Officer | Open-market purchase | Warrant to Purchase Common Stock | 9,000 | - | - | |
| John Micek | Open-market purchase | Convertible Promissory Note | 9,000 | $23,863,636.36 | $450.00M | |
| John Micek | Open-market purchase | Warrant to Purchase Common Stock | 9,000 | - | - | |
| James J. Bochnowski | Open-market purchase | Convertible Promissory Note | 27,002 | $71,590,909.09 | $4.05B | |
| James J. Bochnowski | Open-market purchase | Warrant to Purchase Common Stock | 27,002 | - | - | |
| Jonathan S. Wolin - Officer | Grant or award | Common Stock | 4,922 | $0.00 | - | |
| Jonathan S. Wolin - Officer | Grant or award | Stock option (right to buy) | 39,376 | $0.00 | - | |
| Carol R. Lizak - Officer | Grant or award | Common Stock | 4,280 | $0.00 | - | |
| Carol R. Lizak - Officer | Grant or award | Stock option (right to buy) | 34,240 | $0.00 | - | |
| Steven R. King - Officer | Grant or award | Common Stock | 4,922 | $0.00 | - | |
| Steven R. King - Officer | Grant or award | Stock option (right to buy) | 39,376 | $0.00 | - | |
| John Micek | Grant or award | Stock option (right to buy) | 26,500 | $0.00 | - | |
| Anula Jayasuriya | Grant or award | Stock option (right to buy) | 21,000 | $0.00 | - | |
| Jonathan B. Siegel | Grant or award | Stock option (right to buy) | 26,500 | $0.00 | - | |
| James J. Bochnowski | Grant or award | Stock option (right to buy) | 23,200 | $0.00 | - | |
| Lisa A. Conte - Officer | Grant or award | Common Stock | 16,503 | $0.00 | - | |
| Lisa A. Conte - Officer | Grant or award | Stock option (right to buy) | 132,020 | $0.00 | - | |
| Pravin R. Chaturvedi - Officer | Grant or award | Common Stock | 4,922 | $0.00 | - | |
| Pravin R. Chaturvedi - Officer | Grant or award | Stock option (right to buy) | 39,376 | $0.00 | - |
Jaguar Health, Inc. (JAGX) has filed no insider reports in the last 90 days. The most recent on record is dated 2026-03-12. The full record for JAGX runs to 20 Form 4 filings, the earliest from 2024-10-10. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of JAGX were filed in the last 90 days. 6 purchases are on record for this company.
No insider sales of JAGX were filed in the last 90 days.
This page tracks JAGX Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add JAGX to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
